The rise of Spain: A key player in global clinical trials2 days agoRoohi Mariam PeterBy Roohi Mariam Petermore_vert
Biologics testing: The right time to move to new standards?Apr 30Ute BoronowskyBy Ute Boronowskymore_vert
Can Brazil make cell and gene therapy costs affordable for all?Apr 29Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Overcoming toxicities: are IL-2 smart cytokines the next big thing?Apr 24Roohi Mariam PeterBy Roohi Mariam Petermore_vert
What you need to know to become a research assistantApr 26Roohi Mariam PeterBy Roohi Mariam Petermore_vert
8 of the most expensive drugs in biopharma: Unraveling the costliest medicationsApr 25Willow Shah-nevilleBy Willow Shah-nevillemore_vert
How to overcome rare disease clinical trial challenges?Apr 23Ute BoronowskyBy Ute Boronowskymore_vert
The biggest private biotech investments in March 2024Apr 22Willow Shah-nevilleBy Willow Shah-nevillemore_vert
WuXi AppTec controversy: A catalyst for national security vigilanceApr 18Jules AdamBy Jules Adammore_vert
Duchenne muscular dystrophy: New treatments leading the way5 days agoJules AdamBy Jules Adammore_vert
5 RNA editing companies you should know aboutApr 19Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Small but mighty: The role of small-molecule drugs in disease treatmentApr 17Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Seven groundbreaking mRNA companies to look out forApr 11Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Seven diseases that CRISPR technology could cureApr 4Clara RodrÃguez FernándezBy Clara RodrÃguez Fernándezmore_vert
Doloromics: Revolutionizing chronic pain treatment with omicsApr 12Jim CornallBy Jim Cornallmore_vert
Does the FDA need to tighten its grip on drug trials in the U.S.?Apr 15Roohi Mariam PeterBy Roohi Mariam Petermore_vert
6 biotechnology universities in the USA developing young talentApr 12Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Colossal Biosciences aims to revive the woolly mammoth by 2028Apr 8Jim CornallBy Jim Cornallmore_vert
Are these T cell receptor (TCR) therapy companies on your radar?Apr 1Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Amycretin: Novo Nordisk's new rival to Wegovy in obesity treatmentMar 27Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Are molecular glues the key to undruggable targets?Mar 26Roohi Mariam PeterBy Roohi Mariam Petermore_vert
Advances in Rett syndrome treatment: the rise of gene therapyMar 14Roohi Mariam PeterBy Roohi Mariam Petermore_vert
6 biotechnology universities in the UK leading the way for future talentMar 22Willow Shah-nevilleBy Willow Shah-nevillemore_vert
7 oncolytic virus companies revolutionizing cancer treatmentMar 18Willow Shah-nevilleBy Willow Shah-nevillemore_vert
6 antibiotic companies fighting antimicrobial resistanceMar 7Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Programmable genomic integration: the zenith of genomic medicineMar 1Jim CornallBy Jim Cornallmore_vert
The biggest private biotech investments in February 2024Mar 6Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Is biotechnology a good career? Here are the pros and consMar 15Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Fourteen thriving biotech companies above $100 billion market capMar 13Jules AdamBy Jules Adammore_vert
New non-opioid pain medication: what is in the pipeline?Feb 29Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Terran Biosciences: Redefining neuro treatment with psychedelicsMar 25Jim CornallBy Jim Cornallmore_vert
Beyond fundraising: how do venture capitals build early-stage biotechs?Feb 28Roohi Mariam PeterBy Roohi Mariam Petermore_vert
TIL therapy triumph: A milestone in cancer treatmentFeb 22Roohi Mariam PeterBy Roohi Mariam Petermore_vert
6 pediatric companies revolutionizing children's careFeb 29Willow Shah-nevilleBy Willow Shah-nevillemore_vert
Is Novo Nordisk's Catalent deal shaping a new era in biopharma?Feb 27Jules AdamBy Jules Adammore_vert
Biogen: how is the biotech pivoting from a failed Alzheimer's drug?Feb 15Jules AdamBy Jules Adammore_vert